Start Up of the Month

News

Lipidosa Project: advancing oral delivery of challenging APIs with tetraetherlipid formulations.

Lipidosa Project Kick-Off

We are excited to announce the start of our Lipidosa Project in colaboration with Joanneum Graz, running from July 2025 to June 2027, focused on the pharmacological characterization of tetraetherlipid formulations for oral administration.

One of the greatest challenges in drug development is ensuring that active pharmaceutical ingredients (APIs) reach their target in the body at the right place, in the right dosage, and at the right time.

While oral administration is the most conveniat, and most preferred route for patients, many promising APIs face critical limitations: degradation in the harsh environment of the digestive tract or insufficient absorption across the intestinal barrier. These issues lead to poor bioavailability, preventing their full therapeutic potential from being realized.

Through Lipidosa, NovoArc aims to unlock new possibilities for stable and efficient oral drug delivery by leveraging our unique tetraetherlipid technology.

D2R Project Spotlight: NovoArc contributing lipid innovation for next-generation mRNA vaccine delivery.

NovoArc Joins D2R Project Spotlight Collaboration

We are proud to announce our participation in the D2R Project Spotlight, a collaborative effort with leading researchers from McGill University, Dalhousie University, the University of Calgary, and RNA Technologies and Therapeutics.
This project focuses on the development of a rapid antigen identification platform, with the aim of accelerating next-generation mRNA vaccine development and enabling faster responses to emerging infectious diseases an urgent need that remains highly relevant in the post-COVID era.
As part of this initiative, NovoArc contributes its lipid-based formulation technology to advance innovative solutions for efficient mRNA vaccine delivery.

Read more
Oliver Spadiut presenting NovoArc’s lipid innovation at Advanced Therapies 2025 in London.

NovoArc Showcased at Advanced Therapies 2025

We are proud to share that our Co-founder and CPO, Oliver Spadiut, delivered an inspiring talk during the Innovation Session at the Advanced Therapies Conference 2025 in London.

He presented how NovoArc’s next-generation lipid platform is redefining drug delivery by enabling the oral administration of biologics, small molecules, and nucleic acids.

🔑 Key insight from the session: Stability and efficient delivery remain central challenges in therapeutic development. NovoArc’s lipid technology offers a breakthrough solution to address these barriers and unlock new possibilities in advanced therapies.

Read more

NovoArc GmbH has won the Phönix Start-up Award!

NovoArc GmbH has won the Phönix Start-up Award! Receiving this prestigious prize at the Haus der Industrie Industriellenvereinigung was an unforgettable moment in an amazing atmosphere – a recognition of the hard work we’ve put in over the past years.

Read more

Meet us at BIO-Europe 2024

Excited to be attending BIO-Europe in Stockholm, Sweden from November 4–6, 2024! Looking forward to connecting and exchanging insights. See you there!

8th International Symposium on Phospholipids in Pharmaceutical Research

I had the pleasure of speaking at the 8th International Symposium on Phospholipids in Pharmaceutical Research last week, where there was even a dedicated session on Tetraether lipids—an exciting development for a field that’s gaining momentum.

The event was full of insightful presentations and engaging discussions, and it was a privilege to be part of it.

A big thank you to everyone who made the event a success! Looking forward to more exciting developments in the future.

Read more
Previous Next